MADISON, Wis.–Roche NimbleGen (SWX:RO) (SWX:ROG) (Pink Sheets: RHHBY) is pleased to announce that Eurofins MWG Operon, an Ebersberg, Germany-based company, has officially become a Certified Service Provider (CSP) for NimbleGen Sequence Capture. They will provide services for NimbleGen Titanium Optimized Sequence Capture coupled with sequencing services from 454 Life Sciences, a Roche Company. Eurofins MWG Operon has passed a rigorous certification test plan to achieve precise experimental standards to officially become part of the Roche NimbleGen Certified Service Provider Program. Their certification marks the first genomic service provider to join the global Roche NimbleGen CSP Program in Europe. They will process customer gDNA samples for genomic enrichment using the complete NimbleGen Sequence Capture workflow optimized for 454 Titanium sequencing using 385K Arrays (capture of up to 5 Mb custom regions).

“The Sequence Capture technology of Roche NimbleGen is a perfect fit to our next-generation sequencing platform,” said Bruno Poddevin, Ph.D., Head of Eurofins Genomic Services, “and contributes significant speed and an optimized workflow to support our position as a leading provider of state-of the art services to our customers.”

“Roche NimbleGen welcomes Eurofins MWG Operon as our first European certified service provider for our innovative Sequence Capture technology. We anticipate that our relationship with Eurofins MWG Operon will result in significant growth for the targeted resequencing market and will serve as a model CSP to further expand our service channels on a country, regional, and global level,” said Dr. Gerd Maass, CEO of Roche NimbleGen, Inc.

For more information about Roche NimbleGen, please visit www.nimblegen.com

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients.

In 2008, Roche had over 80,000 employees worldwide and invested almost 9 billion Swiss francs in R&D. The Group posted sales of 45.6 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.

About Eurofins MWG Operon

Eurofins MWG Operon, a member of the Eurofins Group with major offices and production places in Europe, the United States and Asia, is an international provider of DNA sequencing services, gene synthesis, DNA/siRNA synthesis products and bioinformatic services for academic and industrial research. The company’s main mission is to provide best in class services to its customers including high quality standards and innovative solutions for a broad range of applications. As a consequence, Eurofins MWG Operon has continuously extended its next-generation sequencing service offerings including the Genome Sequencer FLX technology and has now become a certified service provider for NimbleGen Sequence Capture.

For more information about Eurofins MWG Operon, please visit www.eurofinsdna.com.

All products are sold for life science research use only. Not for use in diagnostic procedures.

454, 454 LIFE SCIENCES, GS FLX, and NIMBLEGEN are trademarks of Roche.

Other brands or product names are trademarks of their respective holders.